Molecular classification of 46 newly diagnosed DLBCLs
DLBCL . | GCBL/Type 3/ABL . | % malignant cells . | t(14;18): karyotype . | t(14;18): PCR . | REL copy no. . | % REL-positive nuclei . |
|---|---|---|---|---|---|---|
| 1 | ABL | 90 | - | - | 2 | 12 |
| 2 | GCBL | 85 | - | - | 3 | 15 |
| 3 | Type 3 | 90 | - | - | 2 | NE |
| 4 | Type 3 | 70 | NE | NE | 2 | 2 |
| 5 | ABL | 90 | N | - | 1 | 90 |
| 6 | ABL | 50 | - | - | 2 | 80 |
| 7 | ABL | 90 | NE | NE | 3 | NE |
| 8 | GCBL | 90 | F | + | 2 | 85 |
| 9 | GCBL | 80 | + | + | 2 | 50 |
| 10 | ABL | 50 | - | NE | 4 | 95 |
| 11 | ABL | 90 | + | - | 2 | 90 |
| 12 | GCBL | 50 | F | - | 5 | 20 |
| 13 | Type 3 | 90 | F | - | 2 | 40 |
| 14 | GCBL | 95 | - | NE | 2 | 40 |
| 15 | GCBL | 95 | + | + | 2 | 5 |
| 16 | GCBL | 90 | + | + | 1 | 5 |
| 17 | Type 3 | 85 | - | - | 5 | 85 |
| 18 | GCBL | 60 | - | NE | 2 | 90 |
| 19 | GCBL | 75 | + | + | 1 | NE |
| 20 | GCBL | 90 | - | NE | 5 | 10 |
| 21 | Type 3 | 95 | F | NE | 1 | 20 |
| 22 | ABL | 40 | - | - | 1 | 70 |
| 23 | ABL | 30 | N | - | 2 | 25 |
| 24 | Type 3 | 85 | - | - | 1 | NE |
| 25 | Type 3 | 90 | - | - | 3 | 2 |
| 26 | GCBL | 95 | F | - | 2 | 80 |
| 27 | GCBL | 85 | - | - | 4 | 90 |
| 28 | GCBL | 90 | - | - | 3 | 95 |
| 29 | ABL | 30 | F | NE | NE | 90 |
| 30 | Type 3 | 60 | F | - | 5 | NE |
| 31 | Type 3 | 65 | F | - | 1 | 5 |
| 32 | ABL | 85 | + | + | 2 | NE |
| 33 | GCBL | 30 | + | NE | 1 | 5 |
| 34 | ABL | 95 | - | NE | 4 | NE |
| 35 | ABL | 40 | - | - | 2 | 10 |
| 36 | Type 3 | 95 | - | - | 2 | 90 |
| 37 | Type 3 | 90 | F | - | 2 | 95 |
| 38 | ABL | 95 | - | - | 2 | 50 |
| 39 | GCBL | 95 | NE | NE | NE | 15 |
| 40 | ABL | 90 | NE | NE | NE | 90 |
| 41 | Type 3 | 90 | F | - | 1 | 85 |
| 42 | GCBL | 90 | - | + | 4 | 15 |
| 43 | GCBL | 95 | N | NE | 2 | 5 |
| 44 | Type 3 | 50 | F | - | 2 | 20 |
| 45 | GCBL | 95 | - | - | 1 | 85 |
| 46 | GCBL | 80 | - | - | 141 | 1 |
DLBCL . | GCBL/Type 3/ABL . | % malignant cells . | t(14;18): karyotype . | t(14;18): PCR . | REL copy no. . | % REL-positive nuclei . |
|---|---|---|---|---|---|---|
| 1 | ABL | 90 | - | - | 2 | 12 |
| 2 | GCBL | 85 | - | - | 3 | 15 |
| 3 | Type 3 | 90 | - | - | 2 | NE |
| 4 | Type 3 | 70 | NE | NE | 2 | 2 |
| 5 | ABL | 90 | N | - | 1 | 90 |
| 6 | ABL | 50 | - | - | 2 | 80 |
| 7 | ABL | 90 | NE | NE | 3 | NE |
| 8 | GCBL | 90 | F | + | 2 | 85 |
| 9 | GCBL | 80 | + | + | 2 | 50 |
| 10 | ABL | 50 | - | NE | 4 | 95 |
| 11 | ABL | 90 | + | - | 2 | 90 |
| 12 | GCBL | 50 | F | - | 5 | 20 |
| 13 | Type 3 | 90 | F | - | 2 | 40 |
| 14 | GCBL | 95 | - | NE | 2 | 40 |
| 15 | GCBL | 95 | + | + | 2 | 5 |
| 16 | GCBL | 90 | + | + | 1 | 5 |
| 17 | Type 3 | 85 | - | - | 5 | 85 |
| 18 | GCBL | 60 | - | NE | 2 | 90 |
| 19 | GCBL | 75 | + | + | 1 | NE |
| 20 | GCBL | 90 | - | NE | 5 | 10 |
| 21 | Type 3 | 95 | F | NE | 1 | 20 |
| 22 | ABL | 40 | - | - | 1 | 70 |
| 23 | ABL | 30 | N | - | 2 | 25 |
| 24 | Type 3 | 85 | - | - | 1 | NE |
| 25 | Type 3 | 90 | - | - | 3 | 2 |
| 26 | GCBL | 95 | F | - | 2 | 80 |
| 27 | GCBL | 85 | - | - | 4 | 90 |
| 28 | GCBL | 90 | - | - | 3 | 95 |
| 29 | ABL | 30 | F | NE | NE | 90 |
| 30 | Type 3 | 60 | F | - | 5 | NE |
| 31 | Type 3 | 65 | F | - | 1 | 5 |
| 32 | ABL | 85 | + | + | 2 | NE |
| 33 | GCBL | 30 | + | NE | 1 | 5 |
| 34 | ABL | 95 | - | NE | 4 | NE |
| 35 | ABL | 40 | - | - | 2 | 10 |
| 36 | Type 3 | 95 | - | - | 2 | 90 |
| 37 | Type 3 | 90 | F | - | 2 | 95 |
| 38 | ABL | 95 | - | - | 2 | 50 |
| 39 | GCBL | 95 | NE | NE | NE | 15 |
| 40 | ABL | 90 | NE | NE | NE | 90 |
| 41 | Type 3 | 90 | F | - | 1 | 85 |
| 42 | GCBL | 90 | - | + | 4 | 15 |
| 43 | GCBL | 95 | N | NE | 2 | 5 |
| 44 | Type 3 | 50 | F | - | 2 | 20 |
| 45 | GCBL | 95 | - | - | 1 | 85 |
| 46 | GCBL | 80 | - | - | 141 | 1 |
NE indicates not evaluable; N, normal; F, failure.